A P1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Tocagen
- 07 Aug 2018 According to a Tocagen media release, data from this study will be presented at the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.
- 21 May 2018 Status changed from active, no longer recruiting to completed.
- 10 May 2018 Results were presented the 2018 American Academy of Neurology (AAN) Annual Meeting and 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History